Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XW Labs Starts Phase I Trial of Novel Narcolepsy Candidate

publication date: Mar 12, 2018

XW Labs, a CNS company with R&D operations in Wuhan and Taipei, will start an Australian Phase I trial of its lead candidate. XW10172 is a small molecule treatment aimed at narcolepsy. The trial will enroll patients who have type 1 narcolepsy with excessive daytime sleepiness and cataplexy (the sudden onset of muscle weakness following strong emotions). According to XW, current treatments for narcolepsy that address EDS and cataplexy are often associated with limiting side-effects and poor compliance. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital